Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...
Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...
More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...
Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...
A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...
Pfizer partners with Cipla, granting exclusive rights to market key medicines, including Corex Dx and Corex LS, in India.
4don MSN
Where Will Pfizer Be in 5 Years?
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...
We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...
US pharma major Pfizer (NYSE: PFE) has reported the death of a participant enrolled in a long-term extension study of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback